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Abstract
Background: Pulmonary fibrosis is a progressive and lethal disorder. Although the precise mechanisms of
pulmonary fibrosis are not fully understood, oxidant/antioxidant and Th1/Th2 balances may play an important role
in many of the processes of inflammation and fibrosis. The transcription factor Nrf2 acts as a critical regulator for
various inflammatory and immune responses by controlling oxidative stress. We therefore investigated the
protective role of Nrf2 against the development of pulmonary fibrosis.
Methods: To generate pulmonary fibrosis, both wild-type C57BL/6 mice and Nrf2-deficient mice of the same
background were administered bleomycin intratracheally.
Results: The survival of Nrf2-deficient mice after bleomycin administration was significantly lower than that of wild-
type mice. The degree of bleomycin-induced initial pulmonary inflammation and pulmonary fibrosis was much
more severe in Nrf2-deficient mice than in wild-type mice. The expression of antioxidant enzymes and phase II
detoxifying enzymes was significantly reduced in the lungs of Nrf2-deficient mice, concomitant with an elevation
of lung 8-isoprostane level, compared with wild-type mice. The expression of Th2 cytokines, such as interleukin-4
and interleukin-13, was significantly elevated in the lungs of Nrf2-deficient mice with an increase in the number of
Th2 cells that express GATA-binding protein 3.
Conclusions: The results indicated that Nrf2 protects against the development of pulmonary fibrosis by regulating
the cellular redox level and lung Th1/Th2 balance. Thus, Nrf2 might be an important genetic factor in the
determination of susceptibility to pulmonary fibrosis.
Introduction
Pulmonary fibrosis is a chronic progressive disorder in
which excessive deposition of extracellular matrix as a
result of tissue injury leads to irreversible scarring of
interstitial lung tissue [1,2]. Although the precise patho-
logic mechanisms of pulmonary fibrosis are not fully
u n d e r s t o o d ,f i b r o s i si st h o ught to be the result of an
aberrant wound-healing response to sequential lung
injury [3].
Oxidative stress may play an important role in this
process because excessive levels of reactive oxygen spe-
cies (ROS) may damage cellular macromolecules such as
DNAs, lipids, and proteins, leading to oxidative stress-
induced tissue injury [4,5]. To limit the potential toxicity
of ROS, animals possess several cellular and extracellular
enzymatic and small molecular antioxidant systems.
Among these, classic antioxidant enzymes, including
superoxide dismutases, catalase, and glutathione peroxi-
dases, directly inactivate ROS and prevent ROS-initiated
reactions [6]. Phase II detoxifying enzymes, including
glutathione-S-transferase (GSTs), NADP(H): quinone
oxidoreductase (NQO1), and glutamate-cysteine ligase
catalytic (GCLC), also indirectly act as antioxidant
enzymes by controlling biosynthesis/recycling of thiols
or facilitating excretion of oxidized reactive secondary
metabolites. In addition, stress-response proteins
such as heme oxygenase-1 (HO-1) and peroxiredoxin
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prooxidant insults [7,8]. The decreased glutathione
levels observed in the bronchoalveolar lavage (BAL)
fluids and sputum of patients with idiopathic pulmonary
fibrosis suggested that antioxidant capacity is decreased
in the lungs of patients with this disease [9].
There are several factors that modify wound healing
and the degree of fibrosis. Among them, an inflamma-
tory phenotype (Th1 or Th2) is thought to be important
as a host factor to modulate tissue injury and fibrosis. In
idiopathic pulmonary fibrosis, the inflammatory
response closely resembles a Th2-type immune
response, with increases in the number of eosinophils
and mast cells, and increased amounts of Th2 cytokines
such as interleukin (IL)-4 and IL-13 [10,11]. In murine
m o d e l s ,a n i m a l sw h o s er e s p o n s et ot i s s u ei n j u r yi sp r e -
dominantly of the Th2 type are more prone to pulmon-
ary fibrosis after lung injury than those with a
predominantly Th1 response [12].
Nrf2 is a member of the family of cap’n’collar basic
leucine zipper transcription factors and has been identi-
fied as a pivotal factor in the coordinated induction of
antioxidant and phase II detoxifying enzymes under the
regulatory influence of the antioxidant response element
(ARE) [13,14]. Indeed, Nrf2 plays essential roles in pro-
tection against oxidant-induced pulmonary inflamma-
tion and fibrosis [15-18]. Recent studies have
demonstrated that Nrf2 also modifies Th1/Th2 skewing
by regulating oxidative stress [19,20]. It is therefore
likely that Nrf2 is a critical host factor in the determina-
tion of individual susceptibility to pulmonary fibrosis. In
t h ep r e s e n ts t u d y ,w ei n v e s t i g a t e dt h ep r o t e c t i v er o l eo f
Nrf2 against the development of bleomycin-induced pul-
monary inflammation and fibrosis at the cellular and
molecular levels using mice lacking Nrf2.
Methods
Animals and exposure to bleomycin
Nrf2-deficient (Nrf2-/-) mice with an ICR/129sv back-
ground were backcrossed with C57BL/6 mice for eight
generations. C57BL/6 WT mice were purchased from
Charles River Japan (Kanagawa, Japan). All the mice
used in this study were 6 to 8 weeks old and maintained
in our animal facilities under specific pathogen-free con-
ditions. All animal studies were approved by the Institu-
tional Review Board. Mice were administered bleomycin
(5 mg/kg; Calbiochem, San Diego, CA) or saline
intratracheally.
Histopathologic assessment
The lungs were removed 1, 3, and 28 days after bleomy-
cin or saline administration. Following fixation, the
lungs were embedded in paraffin. The sections were
then stained with Masson’s trichrome stain. The grade
of pulmonary fibrosis was scored on a scale of 0 to 8
using a previously described scoring method [21]. After
the examination of 30 randomly chosen regions in each
sample at a magnification of × 100, the mean score of
all the fields was taken as the fibrosis score in each
sample.
Assessment of collagen synthesis
Collagen synthesis was assessed using a hydroxyproline
assay. The mice were anesthetized, and the lungs were
removed 28 days after bleomycin or saline administra-
tion. Hydroxyproline content was measured as reported
previously [22].
Bronchoalveolar lavage (BAL)
The lungs of terminally anesthetized mice were lavaged
with six sequential 1 ml aliquots of PBS 1, 3, and 8 days
after bleomycin administration. Following centrifugation,
the supernatant of the first BAL was used for analysis of
lactate dehydrogenase (LDH) activity using standard
NADH-linked enzymatic assay procedures as previously
described [23]. Cells were counted using a hemocyt-
ometer and a differential cell count was performed by
standard light microscopy based on staining with Diff-
Quik (American Scientific Product, Obetz, OH).
Measurement of cytokines
The concentrations of tumor necrosis factor (TNF)-a
and macrophage inflammatory protein-2 (MIP-2) in the
s u p e r n a t a n to ft h ef i r s tB A Lf l u i dw e r ed e t e r m i n e db y
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (TNF-a :B i o S o u r c e
International, Camarillo, CA; MIP-2: R&D systems,
Minneapolis, MN). The concentrations of IL-4, IL-13,
and interferon-g (IFN-g) in the lung homogenates were
also determined by ELISA (R&D systems).
Reverse transcription-polymerase chain reaction (RT-PCR)
Seven days after bleomycin or saline administration,
total RNA was extracted from lung tissues, and real-
time quantitative RT-PCR was performed using an
ABI7700 sequence detector (Applied Biosystems, Foster
City, CA). The ready-made PCR primers of GST-P1,
GCLS, NQO1, Prx-I, HO-1, T-bet, and GATA-binding
protein 3 (GATA3; Applied Biosystems) were used in
this study. The results were normalized by GAPDH
gene expression.
Measurement of 8-isoprostane
The concentration of 8-isoprostane in the lung homoge-
nates was determined by ELISA (Cayman Chemicals,
Ann Arbor, MI).
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Seven days after bleomycin or saline administration, the
lungs were removed, minced, and incubated with RPMI
1640 containing 10% fetal bovine serum and 75 U/ml
collagenase (type 1; Sigma Chemical Co., St. Louis, MO)
at 37°C for 90 minutes. The cells were then filtered
through 20-μm nylon mesh. The cell suspensions were
stained with anti-CD4, anti-CD8, anti-CXCR3, and anti-
CCR3 antibodies (BD PharMingen, San Diego, CA),
respectively. After staining, the cells were analyzed by
flow cytometry using a FACSCaliber flow cytometer
with CellQuest software (BD Biosciences, San Jose, CA).
Levels of IFN-g and IL-4 production in T cells were
determined by flow cytometric intracellular cytokine
analysis as previously described [24]. Briefly, the cells
were resuspended in RPMI 1640 containing 10% FCS,
incubated with PMA (50 ng/ml; Sigma) and ionomycin
(500 ng/ml; Sigma) for 2 h, and then incubated with
brefeldin A (10 μg/ml; Sigma) for 2 h at 37°C. The cells
were stained with PE-conjugated anti-mouse IFN-g or
with APC-conjugated anti-mouse IL-4 antibodies (BD
PharMingen) and fixed with 2% paraformaldehyde-PBS
solution.
Western blotting
One day after bleomycin or saline administration, the
lungs were removed and nuclear fractions were prepared
using a Nuclear Extraction Kit (Panomics, Redwood
City, CA) according to the manufacturer’s protocol. The
nuclear proteins were separated on 5-15% gradient SDS-
polyacrylamide gels and transferred onto a polyvinyli-
dene difluoride membrane. The membrane was stained
immunochemically using an antibody against nuclear
factor-B (NF-kB) p65 subunit (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). Immunoreactive bands were
detected using ECL Western blotting detection reagents
(Amersham, Buckinghamshire, UK). Lamin B was used
as an internal control.
Statistics
Data were expressed as the mean ± SEM. Comparisons
of data among the experimental groups were performed
using ANOVA and Scheffe’s test. The survival curves
were analyzed using the log-rank test. Values of
p < 0.05 were considered to be statistically significant.
Results
Nrf2-/- mice are highly susceptible to bleomycin
We first evaluated the survival of mice after bleomycin
administration. Forty-five percent of the WT C57BL/6
mice and seventy-five percent of the Nrf2-/- mice died
within 28 days after bleomycin administration (Figure 1).
The survival rate after bleomycin treatment was signifi-
cantly decreased in Nrf2-/- mice compared with WT
mice. No mice died in the saline-administered control
group of either genotype (Figure 1).
Bleomycin-induced initial pulmonary inflammation is
enhancedin Nrf2-/- mice
We assessed the degree of bleomycin-induced acute
lung inflammation in both WT mice and Nrf2-/- mice.
At the light microscopic level, inflammatory cell infiltra-
tion into the airspaces and alveolar septal edema, which
are characteristic pathological findings of acute lung
injury, were observed in the lungs of both genotypes of
mice 1 day and 3 days after bleomycin administration
(Figure 2A, Day 1 and Day 3). However, the degree of
acute lung injury was much more severe in the lungs of
Nrf2-/- mice, compared with WT mice, at both 1 day
and 3 days (Figure 2A, Day 1 and Day 3). No pathologi-
cal abnormalities were observed in the lungs of either
genotype before bleomycin administration (Figure 2A,
Before).
We next assessed the number of inflammatory cells in
BAL fluid. The number of total cells recovered by BAL
increased after bleomycin administration in both geno-
types of mice. Between the genotypes, the number of
total cells in BAL fluid was significantly higher in
Nrf2-/- mice than in WT mice 1 day after bleomycin
administration (Figure 2B, Total cells). The number of
lavageable neutrophils was significantly higher in Nrf2-/-
mice than in WT mice at 1 and 3 days after bleomycin
administration (Figure 2B, Neutrophils). Although the
numbers of macrophages and lymphocytes in BAL fluid
were increased in both genotypes after bleomycin
administration, the numbers were not significantly dif-
ferent between the genotypes (Figures 2B, Macrophages
and Lymphocytes).
We next assessed the lung wet-dry ratio and LDH
activity in BAL fluid as indicators of lung permeability
damage and lung cell damage, respectively. The lung
wet-dry ratio was significantly higher in Nrf2-/- mice
than in WT mice at both 1 and 3 days after bleomycin
administration (Figure 2C). LDH activity in BAL fluid
was also significantly higher in Nrf2-/- mice than in WT
mice at both 1 and 3 days after bleomycin administra-
tion (Figure 2D). These findings suggest that mice lack-
ing Nrf2 are more susceptible to bleomycin-induced
acute pulmonary inflammation.
Bleomycin-induced pulmonary fibrosis is enhanced in
Nrf2-/-mice
We then assessed the development of bleomycin-
induced pulmonary fibrosis in both WT mice and
Nrf2-/- mice. Masson’s trichrome stain revealed mild
thickening of alveolar septa and collagen deposition 28
days after bleomycin administration in the lungs of WT
mice (Figure 3A, wild-type, bleo). The degree of
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compared with wild-type mice. Dense fibrosis with pro-
minent collagen deposition was observed 28 days after
bleomycin administration in the lungs of Nrf2-/- mice
(Figure 3A, Nrf2-/-, bleo). No abnormal alveolar archi-
tecture was observed in the lungs of the saline-adminis-
tered control group in either WT or Nrf2-/- mice
(Figures 3A, saline).
We next assessed the degree of pulmonary fibrosis
using a scoring method. In both genotypes of mice, the
scores of fibrotic lesions were significantly increased 28
days after bleomycin administration, compared with
those in saline-administered controls (Figure 3B). How-
ever, the scores were significantly higher in Nrf2-/- mice
than in WT mice at that time (Figure 3B).
We further assessed the degree of pulmonary fibrosis
by measuring the lung hydroxyproline content, which
we found to be significantly increased 28 days after
bleomycin administration in both genotypes (Figure 3C).
The concentration, however, was significantly higher in
Nrf2-/- mice than in WT mice at that time (Figure 3C).
These findings suggest that mice lacking Nrf2 are more
susceptible to bleomycin-induced pulmonary fibrosis.
Inflammatory protein expression is enhanced in the lungs
of Nrf2-/-mice
Since neutrophilic pulmonary inflammation was
enhanced in the lungs of Nrf2-/- mice at 1 and 3 days
after bleomycin administration, the levels of TNF-a and
MIP-2 were evaluated in the BAL fluid of both geno-
types of mice at those time points. The concentration of
TNF-a was significantly elevated in the BAL fluid of
Nrf2-/- mice, compared with WT mice, 1 day after bleo-
mycin administration (Figure 4A). The concentration of
MIP-2 was also significantly higher in the BAL fluid of
Nrf2-/- mice than in that of WT mice 1 day after bleo-
mycin administration (Figure 4B). These findings sug-
gest that the pulmonary levels of inflammatory
cytokines and chemokines were elevated in mice lacking
Nrf2 by stimulation with bleomycin.
NF-B is known as a transcription factor that regu-
lates the expression of inflammatory cytokines such as
TNF-a and MIP-2. We therefore assessed the activation
of NF-B in the lungs of both WT mice and Nrf2-/-
mice. The nuclear location of NF-B was elevated in the
lungs of both genotypes 1 day after bleomycin adminis-
tration. However, the degree of NF-B nuclear location
was much higher in the lungs of Nrf2-/- mice than
those of WT mice 1 day after bleomycin administration
(Figure 4C). These findings indicate that activation of
NF-B is enhanced in the lungs of mice lacking Nrf2.
Induction of antioxidant enzymes is attenuated in
Nrf2-/-mice
Oxidative stress may play an important role in the
development of bleomycin-induced pulmonary fibrosis.
We therefore assessed the degree of oxidative stress in
the lungs of both WT mice and Nrf2-/- mice. The con-
centration of 8-isoprostane, a marker of oxidative stress,
was increased significantly in the lung homogenates of
Nrf2-/- mice 1 day after bleomycin administration, com-
pared with that of WT mice (Figure 5A).
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Figure 2 Bleomycin-induced pulmonary inflammation is enhanced in Nrf2-/- mice. (A) Representative photographs of lungs from WT mice
and Nrf2-/- mice before, and 1 day (Day 1), and 3 days (Day 3) after treatment with bleomycin. Magnification: ×40. (B) The numbers of total
cells, macrophages, neutrophils, and lymphocytes in bronchoalveolar lavage fluid of WT mice (open bars) and Nrf2-/- mice (solid bars) before,
and 1 day (Day 1), 3 days (Day 3), and 8 days (Day 8) after treatment with bleomycin. n = 8 in each group. (C) Lung wet-to-dry ratio of WT mice
(open bars) and Nrf2-/- mice (solid bars) before, and 1 day (Day 1), and 3 days (Day 3) after treatment with bleomycin. n = 8 in each group. (D)
The activity of lactate dehydrogenase (LDH) in bronchoalveolar lavage fluid of WT mice (open bars) and Nrf2-/- mice (solid bars) before, and 1
day (Day 1), 3 days (Day 3), and 8 days (Day 8) after treatment with bleomycin. n = 8 in each group. *Significant difference (p<0.05) between WT
mice and Nrf2-/- mice.
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Figure 3 Bleomycin-induced pulmonary fibrosis is enhanced in Nrf2-/- mice. (A) Representative photographs of lungs from WT mice and
Nrf2-/- mice 28 days after treatment with bleomycin (bleo) or saline. Magnification: ×40. (B-C) The score of fibrosis (B) and lung hydroxyproline
contents (C) of WT mice (open bars) and Nrf2-/- mice (solid bars) 28 days after treatment with bleomycin (bleo) or saline. n = 6 in each group.
*Significant difference (p<0.05) between WT mice and Nrf2-/- mice.
Kikuchi et al. Respiratory Research 2010, 11:31
http://respiratory-research.com/content/11/1/31
Page 6 of 12T
N
F
-
α
 
(
p
g
/
m
l
 
B
A
L
F
)
A
Before Day 1 Day 3
200
150
100
0
*
Before Day 1 Day 3
60
40
20
0
*
B
50
M
I
P
-
2
 
(
p
g
/
m
l
 
B
A
L
F
)
C
Before Day 1 Day 3
WT KO WT KO WT KO
p65
Lamin B
Figure 4 Inflammatory protein level and activation of NF-B are elevated in the lungs of Nrf2-/- mice. The concentration of TNF-a (A)
and MIP-2 (B) in bronchoalveolar lavage fluid of WT mice (open bars) or Nrf2-/- mice (solid bars) before, and 1 day (Day 1) and 3 days (Day 3)
after bleomycin administration. n = 4 in each group. *Significant difference (p < 0.05) between WT mice and Nrf2-/- mice. (C) Nuclear
localization of NF-B (p65) in the lungs of WT mice or Nrf2-/- mice (KO) before, and 1 day (Day 1) and 3 days (Day 3) after bleomycin
administration. Lamin B was used as an internal control.
8
-
i
s
o
p
r
o
s
t
a
n
e
 
(
p
g
/
m
l
)
G
S
T
-
P
1
/
G
A
P
D
H
G
C
L
C
/
G
A
P
D
H
N
Q
O
1
/
G
A
P
D
H
H
O
-
1
/
G
A
P
D
H
P
r
x
-
I
/
G
A
P
D
H
A
Before Day 1 Day 3
1200
800
400
0
*
Before Day 1 Day 3
3
2
1
0
*
*
B
Before Day 1 Day 3
6
4
2
0
*
*
8
C
Before Day 1 Day 3
6
4
2
0
*
8
Before Day 1 Day 3
2
1
0
*
3
Before Day 1 Day 3
2
1
0
*
3
*
DE F
Figure 5 Induction of antioxidant genes is attenuated in the lungs of Nrf2-/- mice. (A) The concentration of 8-isoprostane, an oxidative
stress marker, in the lungs of WT mice (open bars) or Nrf2-/- mice (solid bars) before, and 1 day and 3 days after bleomycin administration. n =
4 in each group. (B-F) The expression of GST-P1 (B), GCLC (C), NQO1 (D), HO-1 (E), and PrxI(F) mRNAs in the lungs of WT mice (open bars) or
Nrf2-/- mice (solid bars) before, and 1 day (Day 1) and 3 days (Day 3) after bleomycin administration. GAPDH was used as an internal control.
n = 3 in each group. *Significant difference (p < 0.05) between WT mice and Nrf2-/- mice.
Kikuchi et al. Respiratory Research 2010, 11:31
http://respiratory-research.com/content/11/1/31
Page 7 of 12We next assessed the expression of antioxidant and
glutathione-related enzyme genes, such as GST-P1,
GCLC, NQO1, HO-1, and Prx-I, in the lungs of both
WT mice and Nrf2-/- mice. Messenger RNA expression
of all of these enzymes was significantly induced in the
lungs of WT mice by stimulation with bleomycin. How-
ever, the expression levels of GST-P1, GCLC, and
NQO1 mRNAs were significantly lower in the lungs of
Nrf2-/- mice than in those of WT mice at both 1 and 3
days after bleomycin administration (Figures 5B-5D).
The expression levels of HO-1 and Prx-I mRNAs were
also significantly lower in the lungs of Nrf2-/- mice than
in those of WT mice 3 days after bleomycin administra-
tion (Figures 5E and 5F). These findings indicate that
oxidative stress is enhanced in the lungs of mice lacking
Nrf2 due to the lower induction of antioxidants in
response to bleomycin.
Th2-bias occurs in the lungs of Nrf2-/- mice after
bleomycintreatment
Th2 cytokines play an important role in the pathogen-
esis of pulmonary fibrosis. We therefore assessed Th1/
Th2 cytokine levels in the lungs of both WT mice and
Nrf2-/- mice after bleomycin administration. The
mRNA expression of the Th2 cytokines IL-4 and IL-13
was increased in the lungs of both genotypes after bleo-
mycin administration. However, the expression of both
IL-4 and IL-13 mRNAs was significantly higher in the
lungs of Nrf2-/- mice than in those of WT mice 7 days
after bleomycin treatment (Figure 6A, left and center
panels). Although the expression of IFN-g, a Th1 cyto-
kine, was decreased significantly in the lungs of both
genotypes of mice after bleomycin administration, the
level was not different between WT mice and Nrf2-/-
mice (Figure 6A, right panel).
We then assessed the appearance of Th1 and Th2
cells in the lungs of both WT mice and Nrf2-/- mice
using their cell surface markers CXCR3 and CCR3,
respectively. The proportion of CXCR3-positive cells
among CD4+ T cells was significantly increased in the
lungs of WT mice but not in those of Nrf2-/- mice 7
days after bleomycin administration, compared with the
corresponding saline-administered control. Between the
genotypes, the proportion was significantly lower in
Nrf2-/- mice than in WT mice at that time point (Figure
6B, left panel). Similarly, the proportion of CXCR3-posi-
tive cells among CD8+ T cells was significantly lower in
Nrf2-/- mice than in WT mice 7 days after bleomycin
administration (Figure 6B, middle-left panel). We also
assessed Th1 and Th2 cytokine production in lung T
cells. The proportion of IFN-g-producing cells among
CD4+ T cells was significantly lower in Nrf2-/- mice
than in WT mice 7 days after bleomycin administration
(Figure 6B, middle-right panel). The proportion of IFN-
g-producing cells among CD8+ T cells was significantly
lower in Nrf2-/- mice than in WT mice at that time
point (Figure 6B, right panel).
The proportion of CCR3-positive cells among CD4+ T
cells increased markedly in the lungs of Nrf2-/- mice but
not in those of WT mice 7 days after bleomycin admin-
istration, compared with the saline-administered control.
Between genotypes, the proportion was significantly
higher in Nrf2-/- mice than in WT mice 7 days after
bleomycin administration (Figure 6C, left panel).
Although the proportion of CCR3-positive cells among
CD8+ T cells increased in the lungs of Nrf2-/- mice 7
days after bleomycin administration, compared with the
saline-administered control, the proportion was not dif-
ferent between the mouse genotypes after bleomycin
administration (Figure 6C, middle-left panel). The pro-
portion of IL-4-producing cells among CD4+ T cells
was significantly higher in Nrf2-/- mice than in WT
mice 7 days after bleomycin administration (Figure 6C,
middle-right panel). The proportion of IL-4-producing
cells among CD8+ T cells was also significantly higher
in Nrf2-/- mice than in WT mice at that time point
(Figure 6C, right panel).
The transcription factors T-bet and GATA3 are
known as the master regulators of Th1 and Th2 differ-
entiation, respectively. We therefore assessed the expres-
sion of both T-bet and GATA3 in the lymphocytes
o b t a i n e df r o mt h el u n g so fW Tm i c ea n dNrf2-/- mice.
The expression of T-bet mRNA was decreased by 7
days after bleomycin administration in both genotypes
of mice (Figure 6D, left panel). However, the expression
of T-bet was not different between WT mice and
Nrf2-/- mice (Figure 6C, left panel). The expression of
GATA3 mRNA was elevated in the lungs of Nrf2-/-
mice after bleomycin treatment, while the expression
was not upregulated in the lungs of WT mice after bleo-
mycin administration (Figure 6D, right panel). The
expression of GATA3 was significantly higher in the
lungs of Nrf2-/- mice than in those of WT mice 7 days
after bleomycin treatment (Figure 6D, right panel).
Discussion
In this study, we demonstrated that mice lacking Nrf2
are highly susceptible to bleomycin-induced pulmonary
inflammation and fibrosis. Bleomycin is a chemothera-
peutic drug used for treatment of various human carci-
nomas. It has been reported that administration of a
high-dose of bleomycin often induces acute lung injury
and pulmonary fibrosis in both human and experimental
animals [25,26]. Bleomycin can directly produce ROS
during the process of reaction with DNA [27]. More-
over, bleomycin indirectly increases ROS by activating
inflammatory cells accumulated in the lung to generate
ROS [28,29]. In the present study, the concentration of
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Figure 6 Lung Th1/Th2 balance is shifted toward Th2 in Nrf2-/- mice. (A) The expression of IL-4, IL-13, and IFN-g in the lungs of WT mice
(open bars) or Nrf2-/- mice (solid bars) 7 days after treatment with saline or bleomycin (bleo). GAPDH was used as an internal control. n = 6 in
each group. (B-C) The left panels show the proportion of CXCR3-positive (B) or CCR3-positive (C) cells among CD4-positive cells or among CD8-
positive cells obtained from WT mice (open bars) or Nrf2-/- mice (solid bars) 7 days after treatment with saline or bleomycin (bleo). n = 6 in
each group. The right panels show the proportion of IFN-g-producing (B) or IL-4-producing (C) cells among CD4-positive cells or among CD8-
positive cells obtained from WT mice or Nrf2-/- mice (KO) 7 days after treatment with bleomycin. n = 6 in each group. (D) The expression of T-
bet and GATA-3 in the lymphocytes obtained from the lungs of WT mice (open bars) or Nrf2-/- mice (solid bars) 7 days after treatment with
saline or bleomycin (bleo). GAPDH was used as an internal control. n = 6 in each group. *Significantly different (p < 0.05) between WT mice and
Nrf2-/- mice.
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Page 9 of 128-isoprostane, a marker of oxidative stress, was signifi-
cantly higher in the lungs of Nrf2-/- mice than in those
of WT mice after bleomycin administration. These
results indicate that oxidative stress is enhanced in the
lungs of Nrf2-/- mice after bleomycin administration.
Thus, Nrf2 may be an important host factor to protect
against oxidant-induced tissue damages.
Nrf2-mediated defense mechanisms against oxidative
stress have recently been elucidated at the molecular
level. Under unstimulated conditions, Nrf2 is retained in
the cytoplasm through binding to Kelch-like ECH-asso-
ciated protein-1 (Keap1) and is maintained at a reduced
level by the Keap1-dependent ubiquitination and proteo-
somal degradation systems[30,31]. Upon exposure to
oxidative stress or xenobiotic stress, Keap1-dependent
ubiquitin ligase activity is inhibited and Nrf2 can trans-
locate to the nucleus, where it forms a heterodimer with
small Maf proteins and binds to ARE. Pulmonary Nrf2
effecter genes bearing AREs include a majority of phase
II detoxifying enzymes such as GST isozymes, GCLC,
and NQO1, as well as stress proteins such as HO-1, Prx
I, thioredoxin (Trx), and Trx reductase [32]. In the pre-
sent study, the induction of these cytoprotective genes
following exposure to bleomycin was consistently and
markedly attenuated in the lungs of Nrf2-/- mice relative
to that in the lungs of WT mice. Thus, the reduced
induction of ARE-mediated antioxidant defense enzymes
in the lungs of Nrf2-/- mice suggests that these enzymes
contribute to Nrf2-mediated protection against bleomy-
cin-induced pulmonary inflammation and fibrosis. The
protective role of ARE-mediated antioxidant enzymes in
experimental fibrosis has been demonstrated. Activation
of Nrf2 by a polyphenol epigallocatechin-3-gallate treat-
ment reduced bleomycin-induced lung injury and
inflammation in rats by inducing phase II enzymes such
as GST and NQO1 [33]. The pulmonary fibrosis and
inflammation induced by bleomycin were prevented in
mice overexpressing thioredoxin [34].
Although the pathogenesis of pulmonary fibrosis is
not fully understood, a newer hypothesis suggests that
pulmonary fibrosis is the culmination of the wound-
healing responses to sequential acute lung injury [3].
The fibrotic response itself is modified by the predomi-
nant inflammatory phenotype, either Th1 or Th2.
Although the Th2 and Th1 phenotypes are not as well
defined in idiopathic pulmonary fibrosis as they are in
asthma and animal models, their potential importance is
one rationale for trials in which immunomodulators
such as IFN-g are used in an attempt to switch the
inflammatory responses to a more Th1-like phenotype.
In the present study, we found that the levels of Th2
cytokines IL-4 and IL-13 were elevated in the lungs of
Nrf2-/- mice after bleomycin administration. These cyto-
kines enhance the fibrotic process by augmenting
fibroblast proliferation and collagen production, and are
required for the initiation and maintenance of pulmon-
ary fibrosis [35-37]. Both IL-4 and IL-13 are mainly
produced and secreted by Th2 cells. Consistently, the
present study showed that the proportion of CCR3-
positive Th2 cells was significantly increased while the
proportion of CXCR4-positive Th1 cells was decreased
in the lungs of Nrf2-/- mice after bleomycin administra-
tion. The measurement of intracellular cytokine levels
also revealed that the proportion of IL-4-producing T
cells was increased whereas the proportion of IFN-g-
producing T cells was decreased in the lungs of Nrf2-/-
mice after bleomycin administration. These findings
suggest that the Th1/Th2 balance is shifted toward Th2
in the lungs of Nrf2-/- mice by exposure to bleomycin.
Nrf2 may affect the differentiation and cytokine produc-
tion of T cells rather than baseline homing of Th1/Th2
cells in the lungs, since the level of Th1 and Th2 cells
was not different between the lungs of WT mice and
Nrf2-/- mice under the unstimulated condition.
The differentiation of Th1/Th2 cells is regulated by
the transcription factors T-bet and GATA3, respec-
tively. GATA3, a member of the GATA family of zinc-
finger transcription factors, is known to be a key regu-
lator of Th2 development. It has been demonstrated
that antisense GATA3 inhibits the expression of all
Th2 cytokine genes in the Th2 clone D10 [38]. In
transgenic mice, elevated GATA3 in CD4+ T cells
induces Th2 cytokine gene expression in developing
Th1 cells [38]. It has also been reported that GATA3
regulates the locus accessibility of the IL-4 and IL-13
genes with chromatin remodeling [39,40]. These find-
ings suggest that GATA3 allows the expression of Th2
cytokines by functioning as a transcription factor as
well as by modifying the chromatin structure of these
cytokines. Our previous study demonstrated that the
development of bleomycin-induced pulmonary fibrosis
was significantly enhanced in mice overexpressing
GATA3 with a lung Th2 cytokine bias [41]. In the pre-
sent study, expression of GATA3 was elevated signifi-
cantly in the lymphocytes obtained from the lungs of
Nrf2-/- mice, whereas the GATA3 level was not altered
in the lymphocytes from WT mice after bleomycin
administration. Thus, GATA3-mediated Th2 cell
differentiation and Th2 cytokine induction are an
additional mechanism for aggravation of bleomycin-
induced pulmonary fibrosis in mice lacking Nrf2. The
relationship between Nrf2 and Th2 bias has been
reported previously. Genetic deletion of Nrf2 renders
mice more susceptible to Th2-driven allergic airway
inflammation [42]. Furthermore, stimulation of Nrf2-/-
dendritic cells with ambient particulate matter aug-
mented oxidative stress and Th2 cytokine production
as compared with Nrf2 wild-type dendritic cells [19].
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mice after bleomycin exposure, it has been demon-
strated that oxidative stress favors a Th2-polarizing con-
dition. King et al. have demonstrated that exposure of T
cells to 2,3-dimethoxy-1,4-naphthoquinone, which gen-
erates a low level of superoxide anion, resulted in the
growth of cells expressing CCR4, and a decrease in cells
expressing CXCR3, indicating phenotypic conversion to
Th2 cells by activation of signal transducer and activator
of transcription 6 (STAT6), leading to the induction of
GATA3 [43]. In the present model, we found that phos-
phorylated STAT6 levels were enhanced in the lung
lymphocytes of Nrf2-/- mice after bleomycin exposure
(data not shown). These findings suggest that enhanced
oxidative stress promotes Th2 cell differentiation and
Th2 cytokine production by activating STAT6, followed
by activation of GATA3. Thus, Nrf2 may be a critical
regulator for Th1/Th2 balance in the lungs exposed to
oxidants or electrophiles.
In the present study, the activation of NF-Bw a s
enhanced in the lungs of Nrf2-/- mice after bleomycin
administration. NF-B plays a cardinal role in the devel-
opment of pulmonary inflammation through transcrip-
tional activation of many proinflammatory genes,
including the genes of cytokines and chemokines [44].
In the present study, the levels of TNF-a and MIP-2
were also consistently enhanced in Nrf2-/- mice. NF-B
is known as a redox-sensitive transcription factor that is
activated by ROS [45,46]. It is therefore likely that Nrf2
inhibits the activation of NF-B by reducing cellular oxi-
dant levels. Lung macrophages are thought to be the
p r i m a r ys o u r c eo ft h o s ec y t o k i n e si n d u c e db yN F - B.
We have demonstrated that Nrf2-mediated transcription
of cytoprotective genes is mainly activated in macro-
phages in response to environmental stimuli [47,48]. It
is therefore reasonable to hypothesize that the aberrant
gene expression in Nrf2-/- macrophages may cause an
overwhelming inflammatory response and thus evoke
pulmonary fibrosis.
Conclusions
The present study showed that Nrf2 protects against the
development of bleomycin-induced pulmonary inflam-
mation and fibrosis by regulating the cellular redox level
and Th1/Th2 balance. Nrf2 has an advantage over a sin-
gle antioxidant molecule for the treatment of acute lung
injury and pulmonary fibrosis, since Nrf2 coordinately
induces a variety of self-defense genes, including antioxi-
dant and phase II enzymes. In addition, Nrf2 is
expressed abundantly in macrophages, cells which are
easily collected by BAL. Acute respiratory distress syn-
drome and idiopathic pulmonary fibrosis are lethal dis-
orders for which effective therapeutic approaches are
not readily available. Although transcription factor
regulation therapy cannot currently be used for the
treatment of these diseases, we believe that the present
results may lead to new therapeutic options.
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